Epilepsy Research Institute opens 2025-26 grant round with new awards
Ella Day | August 21, 2025 | News story | Medical Communications, Research and Development | Neurology, epilepsy, funding programme, medical research
The Epilepsy Research Institute has opened its 2025-26 Grant Round, offering a wide range of funding opportunities designed to support researchers at every stage of their careers. The funding reflects the Institute’s commitment to connecting the epilepsy research community.
Applications are invited across all areas of epilepsy research, with new award types introduced this year to encourage innovative projects and leadership development.
The funding includes the Emerging Leader Fellowship Award (up to £300,000), aimed at supporting researchers transitioning to independent leadership; the Endeavour Project Grant (up to £175,000), which will fund hypothesis-driven projects with pilot data; and the Explore Pilot Grant (up to £40,000), tailored for early career researchers seeking to test new ideas.
In addition, several co-funded awards are available. These include the Emerging Leader Fellowship with SUDEP Action, focusing on reducing preventable epilepsy deaths; PhD studentships with Sam’s Superheroes Foundation, dedicated to FIRES and NORSE research; and a joint award with the Anatomical Society for projects in anatomical sciences.
Annee Amjad, head of research & involvement at the Institute, said: “We’re proud to launch this grant round to empower researchers at every stage of their careers and drive forward breakthroughs that will improve the lives of people affected by epilepsy.”
Ben Donovan, research manager at SUDEP Action, added: “There are still too many preventable deaths occurring and research has a critical role to play in both understanding risk and informing practice that can save lives.”
Ella Day
21/8/25
This article featured in: September 2025 – The Pharmafile Brief
Related Content
EpilepsyGTx raises $33m for focal refractory epilepsy gene therapy
EpilepsyGTx, a biotechnology company researching and developing gene therapies for the treatment of refractory epilepsy, …
UCB presents positive results for fenfluramine in CDKL5 deficiency disorder
UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can …
Rare and severe epilepsies – current treatments and advance therapeutics
The current forms of immunotherapy, how T cell therapy works and what the future holds
